IDH1 and neoplasm: Using transducers against a clinically relevant mutation (i.e., IDH1 R132H mutation in brain tumors) (Supplementary Table 2), in patient tumor tissues as well as paired plasma samples with known IDH1 mutation status, we performed the EZ-READ measurements and established accurate tumor classification (overall classification accuracy ≥90%) (Supplementary Fig. 10c).